Aptevo Therapeutics Inc (APVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Sales | 3,665 | 3,096 | 3,110 | 2,421 | 2,373 |
| Gross Profit | 3,665 | 3,096 | 3,110 | 2,421 | 2,373 |
| Operating Expenses | 7,705 | 7,846 | 8,832 | 9,309 | 9,192 |
| Operating Income | -4,040 | -4,750 | -5,722 | -6,888 | -6,819 |
| Other Income | -2,557 | -2,327 | -2,342 | -782 | -352 |
| Pre-tax Income | -6,597 | -7,077 | -8,064 | -7,670 | -7,171 |
| Net Income Continuous | -6,597 | -7,077 | -8,064 | -7,670 | -7,171 |
| Net Income Discontinuous | 325 | 80 | 132 | 414 | 118 |
| Net Income | $-6,272 | $-6,997 | $-7,932 | $-7,256 | $-7,053 |
| EPS Basic Total Ops | -39,902.98 | -45,648.98 | -55,864.13 | -52,352.67 | -61,290.93 |
| EPS Basic Continuous Ops | -41,911.64 | -46,180.41 | -56,738.36 | -55,419.76 | -57,779.48 |
| EPS Basic Discontinuous Ops | 2,033.57 | 522.03 | 928.75 | 2,991.37 | -3,511.46 |
| EPS Diluted Total Ops | -39,902.98 | -45,648.98 | -55,864.13 | -52,352.67 | -61,290.93 |
| EPS Diluted Continuous Ops | -41,911.64 | -46,180.41 | -56,738.36 | -55,419.76 | -57,779.48 |
| EPS Diluted Discontinuous Ops | 2,033.57 | 522.03 | 928.75 | 2,991.37 | -3,511.46 |
| EBITDA(a) | $-3,784 | $-4,455 | $-5,423 | $-6,594 | $-6,477 |